BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37438675)

  • 1. Single-cell transcriptome analysis identifies novel biomarkers involved in major liver cancer subtypes.
    Swain AK; Pandey P; Sera R; Yadav P
    Funct Integr Genomics; 2023 Jul; 23(3):235. PubMed ID: 37438675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
    Bai Y; Tong W; Xie F; Zhu L; Wu H; Shi R; Wang L; Yang L; Liu Z; Miao F; Zhao Q; Zhang Y
    Aging (Albany NY); 2021 Jul; 13(13):17592-17606. PubMed ID: 34237708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.
    Xue TC; Zhang BH; Ye SL; Ren ZG
    Tumour Biol; 2015 Aug; 36(8):5891-9. PubMed ID: 25712376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.
    Likhitrattanapisal S; Tipanee J; Janvilisri T
    Tumour Biol; 2016 Sep; 37(9):12755-12766. PubMed ID: 27448818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma.
    Chaisaingmongkol J; Budhu A; Dang H; Rabibhadana S; Pupacdi B; Kwon SM; Forgues M; Pomyen Y; Bhudhisawasdi V; Lertprasertsuke N; Chotirosniramit A; Pairojkul C; Auewarakul CU; Sricharunrat T; Phornphutkul K; Sangrajrang S; Cam M; He P; Hewitt SM; Ylaya K; Wu X; Andersen JB; Thorgeirsson SS; Waterfall JJ; Zhu YJ; Walling J; Stevenson HS; Edelman D; Meltzer PS; Loffredo CA; Hama N; Shibata T; Wiltrout RH; Harris CC; Mahidol C; Ruchirawat M; Wang XW;
    Cancer Cell; 2017 Jul; 32(1):57-70.e3. PubMed ID: 28648284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.
    Oishi N; Kumar MR; Roessler S; Ji J; Forgues M; Budhu A; Zhao X; Andersen JB; Ye QH; Jia HL; Qin LX; Yamashita T; Woo HG; Kim YJ; Kaneko S; Tang ZY; Thorgeirsson SS; Wang XW
    Hepatology; 2012 Nov; 56(5):1792-803. PubMed ID: 22707408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An asparagine metabolism-based classification reveals the metabolic and immune heterogeneity of hepatocellular carcinoma.
    Bai J; Tang R; Zhou K; Chang J; Wang H; Zhang Q; Shi J; Sun C
    BMC Med Genomics; 2022 Oct; 15(1):222. PubMed ID: 36284275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic values of tissue-resident CD8
    Chen L; Huang H; Huang Z; Chen J; Liu Y; Wu Y; Li A; Ge J; Fang Z; Xu B; Zheng X; Wu C
    World J Surg Oncol; 2023 Apr; 21(1):124. PubMed ID: 37024870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma.
    Hong W; Zhang Y; Wang S; Zheng D; Hsu S; Zhou J; Fan J; Zeng Z; Wang N; Ding Z; Yu M; Gao Q; Du S
    Cancer Lett; 2024 Feb; 582():216594. PubMed ID: 38135208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
    Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell transcriptomics analysis reveals intratumoral heterogeneity and identifies a gene signature associated with prognosis of hepatocellular carcinoma.
    Liang J; Chen W; Ye J; Ni C; Zhai W
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35169832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.
    Murakami Y; Kubo S; Tamori A; Itami S; Kawamura E; Iwaisako K; Ikeda K; Kawada N; Ochiya T; Taguchi YH
    Sci Rep; 2015 Nov; 5():16294. PubMed ID: 26538415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
    Rosenberg N; Van Haele M; Lanton T; Brashi N; Bromberg Z; Adler H; Giladi H; Peled A; Goldenberg DS; Axelrod JH; Simerzin A; Chai C; Paldor M; Markezana A; Yaish D; Shemulian Z; Gross D; Barnoy S; Gefen M; Amran O; Claerhout S; Fernández-Vaquero M; García-Beccaria M; Heide D; Shoshkes-Carmel M; Schmidt Arras D; Elgavish S; Nevo Y; Benyamini H; Tirnitz-Parker JEE; Sanchez A; Herrera B; Safadi R; Kaestner KH; Rose-John S; Roskams T; Heikenwalder M; Galun E
    J Hepatol; 2022 Dec; 77(6):1631-1641. PubMed ID: 35988690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Cell Sequencing Identifies the Heterogeneity of CD8+ T Cells and Novel Biomarker Genes in Hepatocellular Carcinoma.
    Wang H; Fu Y; Da BB; Xiong G
    J Healthc Eng; 2022; 2022():8256314. PubMed ID: 35449866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma subtypes based on metabolic pathways reveals potential therapeutic targets.
    He Z; Chen Q; He W; Cao J; Yao S; Huang Q; Zheng Y
    Front Oncol; 2023; 13():1086604. PubMed ID: 36937389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
    Gao S; Zhang L; Wang H
    Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell transcriptome analysis reveals the metabolic changes and the prognostic value of malignant hepatocyte subpopulations and predict new therapeutic agents for hepatocellular carcinoma.
    Han C; Chen J; Huang J; Zhu R; Zeng J; Yu H; He Z
    Front Oncol; 2023; 13():1104262. PubMed ID: 36860314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.